# A Study of Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Second-Line Nivolumab Monotherapy in Asia

> **NCT03195491** · PHASE3 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 400 (actual)

## Conditions studied

- Lung Cancer
- Non-Small Cell Lung Cancer

## Interventions

- **BIOLOGICAL:** Nivolumab

## Key facts

- **NCT ID:** NCT03195491
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-25
- **Primary completion:** 2021-06-08
- **Final completion:** 2021-06-08
- **Target enrollment:** 400 (ACTUAL)
- **Last updated:** 2024-07-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03195491

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03195491, "A Study of Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Second-Line Nivolumab Monotherapy in Asia". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03195491. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*